Novocure has kicked off the INNOVATE-3 pivotal trial evaluating the efficacy of tumor treating fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer. It marks the beginning of the company's fourth phase III pivotal trial to study solid tumors beyond glioblastoma.